Naming Convention Biosimilars

PLEASE NOTE:   Posts made to this forum should not be considered as the expressed opinions of, nor should be considered endorsed by, the Medication Safety Officer’s Society (MSOS) or the Institute for Safe Medication Practices (ISMP). 

Make sure your email is up-to-date
In order to continue to receive updates from MSOS, as well as forum posts and other valuable information as a member of MSOS, please be sure to update your email address with us, whenever it changes. If you need assistance doing so, please send an email to jrufo@ismp.org. 

7 posts / 0 new
Log in or register to post comments
Last post
Mon, 01/28/2019 - 16:12
#1
Amaris Fuentes
Amaris Fuentes's picture
Offline
Last seen: 4 months 3 weeks ago
Joined: 11/13/2018 - 10:40
Naming Convention Biosimilars

Good afternoon -

As our institution adopts the use of more biosimilar products, the question came up of the appropriate naming convention in the EHR and other places and evaluating possible safety impacts/look-alike, sound-alike risks.

For example, when considering Epoetin alfa (Procrit) vs. Epoetin alfa (Retacrit), is more appropriate to simplify the name or use it's full name of epoetin alfa-epbx (Retacrit)? Our initial thoughts are to use the full name convention with the branded name. Appreciate if anyone has any additional insight or experience with possible medication errors with these drugs.

Thanks

Top